Law360, New York (September 28, 2016, 5:42 PM EDT) -- The continuous stream of performance-enhancing doping news plaguing international sport was headlined recently with an acronym that will be new to probably well over 99 percent of the public: TUE — therapeutic use exemptions. Indeed, that newness illustrates the primary problem with TUEs: They are not at all transparent. Without transparency, it is impossible to analyze other likely ethical problems that TUEs raise.
The idea of a TUE is deceptively simple. An athlete with a medical condition requiring a drug on the World Anti-Doping Agency's list of prohibited substances may apply to that agency for permission to use that drug. What...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!